DOCSLIB.ORG

Download Register

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Download Register ZAMBIA MEDICINES REGULATORY AUTHORITY MEDICINES FOR HUMAN USE 2019 REGISTER S/No Product Name Generic Name Category of Dosage Form Marketing Marketing Authorisation Holder Distribution Authorisation Number Miconazole Nitrate Ceam - 1 A Miconazole Nitrate 20mg POM Cream Topical 046/002 1 A Pharma Gmbh, Germany 1 Pharma cream Cetirizine 10 - 1 A Pharma Cetirizine Dihydrochloride POM Tablet Uncoated 046/003 1 A Pharma Gmbh, Germany 2 tablets 10mg 3 Ateblock - 25 Tablets Atenolol 25mg POM Tablet Uncoated 116/001 AB Lifesciences, India 4 Ateblock - 50 Tablets Atenolol 50mg POM Tablet Uncoated 116/002 AB Lifesciences, India 5 Ateblock - 100 Tablets Atenolol 100mg POM Tablet Uncoated 116/003 AB Lifesciences, India 6 Nosieze Tablets Carbamazepine 400mg POM Tablet Uncoated 116/004 AB Lifesciences, India Amoxicillin Trihydrate POM Capsule Oral 116/006 AB Lifesciences, India Neumox Capsules 7 500mg Sodium Lactate + POM Solution for 316/001 Abacus Parenteral Drugs Ltd, India Sodium Chloride + infusion RL-500 Compound Sodium Potassium Chloride + Lactate Infusion Calcium Chloride 8 Dihydrate NS - 500 Sodium Chloride BP Sodium Chloride POM Solution for 316/002 Abacus Parenteral Drugs Ltd, India 9 Infusion 0.9%w/v infusion Dextrose 5.0g POM Solution for 316/003 Abacus Parenteral Drugs Ltd, India DS-500 Glucose Infusion 10 infusion Betamethasone Soduim POM Solution for Topical 316/004 Abacus Parenteral Drugs Ltd, India X-Beta Eye/Ear Drops 11 Phosphate 0.1% w/v Use Betamethasone Soduim POM Solution for Topical 316/005 Abacus Parenteral Drugs Ltd, India Phosphate 0.1% w/v + Use X- Beta - N Eye/Ear Drops Neomycin sulphate 0.5% 12 w/v Neomycin Sulphate POM Solution for Topical 316/006 Abacus Parenteral Drugs Ltd, India 0.35% w/v + Use X-Sone -N Eye/Ear Drops Dexamethasone 13 Phosphate 0.1% w/v Sodium Chloride 0.9% P Solution for Topical 316/007 Abacus Parenteral Drugs Ltd, India Abnal Nasal Drops 14 w/v Use Mannitol 20 %w/v POM Solution for 316/008 Abacus Parenteral Drugs Ltd, India Abtol 20% Intravenous Infusion 15 infusion Lopinavir 80mg + POM Solution for Oral 128/002 Abbott Laboratories S.A (Pty) Ltd, South Kaletra Solution 16 Ritonavir 20mg, per 5ml Use Africa Page 1 of 320 ZAMBIA MEDICINES REGULATORY AUTHORITY MEDICINES FOR HUMAN USE 2019 REGISTER Klacid P 125 Granules for Clarithromycin 125mg POM Granules for 128/004 Abbott Laboratories S.A (Pty) Ltd, South 17 Suspension Suspension Africa Klacid P 250 Granules for Clarithromycin 250mg POM Granules for 128/005 Abbott Laboratories S.A (Pty) Ltd, South 18 Suspension Suspension Africa Isoflurane 99.9% w/w POM Solution for 128/015 Abbott Laboratories S.A (Pty) Ltd, South Forane Liquid 19 Inhalation Africa Lopinavir 200mg + POM Tablet Film Coated 128/026 Abbott Laboratories S.A (Pty) Ltd, South Aluvia 250/50mg Tablets 20 Ritonavir 50mg Africa Lopinavir 100mg + POM Tablet Film Coated 128/027 Abbott Laboratories S.A (Pty) Ltd, South Aluvia 100/25mg Tablets 21 Ritonavir 25mg Africa Sevoflurane 100% v/v POM Solution for 128/029 Abbott Laboratories S.A (Pty) Ltd, South Ultane Liquid 22 Inhalation Africa Ritonavir USP 100mg POM Tablet, Film Coated 128/030 Abbott Laboratories S.A (Pty) Ltd, South Norvir 100 Tablets 23 Africa Racecaggherdotril 100mg POM Capsule, Oral 128/031 Abbott Laboratories S.A (Pty) Ltd, South Hidrasec Capsules 24 Africa Racecaggherdotril 30mg POM Powder for 128/032 Abbott Laboratories S.A (Pty) Ltd, South Hidrasec Children Sachets 25 Suspension, Oral Africa Racecaggherdotril 10mg POM Powder for 128/033 Abbott Laboratories S.A (Pty) Ltd, South Hidrasec Infant Sachets 26 Suspension, Oral Africa Survanta Intratracheal Total Phospholipids POM Suspension, 128/034 Abbott Laboratories S.A (Pty) Ltd, South 27 Suspension, 4ml Vial 25mg, per ml Intratracheal Africa Calmettes Nite 45mg tablets Valerian Dry Root extract P Tablet Film coated 128/035L Abbott Laboratories S.A (Pty) Ltd, South 28 45mg Africa Calmettes Nite 125mg tablets Valerian Dry Root extract P Tablet Film coated 128/036L Abbott Laboratories S.A (Pty) Ltd, South 29 45mg Africa Mifepristone 200mg + POM Tablet, Uncoated 296/001 Acme Formulation Pvt Ltd, India Mariprist Combikit Tablets 30 Misoprostal 200mcg 31 Misoclear Tablets Misoprostal 200mcg POM Tablet Uncoated 296/002 Acme Formulation Pvt Ltd, India Mannitol 20% w/v POM Solution, Infusion 097/004 Adcock Ingram Pharmaceuticals Ltd, South Sabax Osmitrol 20% Injection 32 Africa Sabax Sodium Chloride 0.9% Sodium Chloride 0.9% POM Solution, Infusion 097/005 Adcock Ingram Pharmaceuticals Ltd, South 33 Injection w/v Africa Dextrose 5 %w/v + POM Solution, Infusion 097/006 Adcock Ingram Pharmaceuticals Ltd, South Sabax Glucose 5% + Sodium Soduim Chloride 0.9 Africa Chloride 0.9% Injection 34 %w/v Page 2 of 320 ZAMBIA MEDICINES REGULATORY AUTHORITY MEDICINES FOR HUMAN USE 2019 REGISTER Sodium chloride + POM Solution, Infusion 097/007 Adcock Ingram Pharmaceuticals Ltd, South Sodium lactate + Africa Sabax Ringer Lactate Injection Potassium chloride + 35 Calcium chloride Peritoneal dialysis POM Solution, Injection 097/008 Adcock Ingram Pharmaceuticals Ltd, South Sabax Dianeal Injection, 1.5% 36 solution 1.5% Africa Peritoneal dialysis POM Solution, Injection 097/009 Adcock Ingram Pharmaceuticals Ltd, South Sabax Dianeal Injection, 2.5% 37 solution 2.5% Africa Peritoneal dialysis POM Solution, Injection 097/010 Adcock Ingram Pharmaceuticals Ltd, South Sabax Dianeal Injection, 4.25% 38 solution 4.25% Africa Paracetamol 250mg + P Capsule Oral 097/011 Adcock Ingram Pharmaceuticals Ltd, South Myprodol Capsules Ibuprofen 200mg + Africa 39 Codeine 10mg Paracetamol 250mg + P Suspension for 097/012 Adcock Ingram Pharmaceuticals Ltd, South Lotem Suspension 40 Ibuprofen 200mg Oral Use Africa Caffeine 30 mg + P Tablet oral 111/005 Adcock Ingram Pharmaceuticals Ltd, South Codeine 10 mg + Africa Syndol Tablets Doxylamine 5 mg + 41 Paracetamol 450 mg Paracetamol 450 mg + P Tablet oral 111/008 Adcock Ingram Pharmaceuticals Ltd, South Codeine phosphate 10 Africa mg + Doxylamine Betapyn Tablets succinate 5 mg + Caffeine alkaloid 50 42 mg Cetylpyridinium chloride GS Lozenges 111/009 Adcock Ingram Pharmaceuticals Ltd, South Medikeel A Throat Lozenges 1.5 mg + benzocaine 12 Africa 43 mg Benzocaine 10 mg + GS Lozenges 111/014 Adcock Ingram Pharmaceuticals Ltd, South Cepacol Throat Regular Cetylpyridinium chloride Africa Lozenges 44 1.47 mg Theophylline 16.667 mg POM Syrup 111/022 Adcock Ingram Pharmaceuticals Ltd, South + Hydroxyethyl Africa Theophylline 1.667 mg + Diphenhydramine HCl Alcophyllex Mixture 6.667 mg + Ammonium Chloride 120 mg + Sodium Citrate 50 mg/5 45 ml Page 3 of 320 ZAMBIA MEDICINES REGULATORY AUTHORITY MEDICINES FOR HUMAN USE 2019 REGISTER Cetylpyridinium Chloride GS Solution for Topical 111/023 Adcock Ingram Pharmaceuticals Ltd, South Cepacol Antibacterial 50 mg + Alcohol 15.8 % Use Africa Mouthwash 46 v/v Cetylpyridinium Chloride GS Lozenges 111/024 Adcock Ingram Pharmaceuticals Ltd, South Cepacol Throat Menthol 1.47 mg + Benzyl Alcohol Africa Lozenges 47 6.5 mg Terbutaline 1.25mg + P Syrup 111/025 Adcock Ingram Pharmaceuticals Ltd, South Ammonium Chloride Africa Bronchoped Syrup 60mg + Sodium Citrate 48 25mg Sodium bicarbonate P Granules for 111/026 Adcock Ingram Pharmaceuticals Ltd, South 1.716mg + Tartaric acid Suspension Africa Citro Soda Orange Granules 856mg + Citric acid 702mg + Sodium citrate 49 613mg Sodium bicarbonate P Granules for 111/027 Adcock Ingram Pharmaceuticals Ltd, South 1.716mg + Tartaric acid Suspension Africa Citro Soda Granules 856mg + Citric acid 702mg + Sodium citrate 50 613mg Sennosides dry extract P Tablet Uncoated 111/028 Adcock Ingram Pharmaceuticals Ltd, South Adco-Senna Tablets 60% eq. to 13.50mg Africa 51 Senoside A & B Lignocaine Hydrochloride POM Solution for 111/029 Adcock Ingram Pharmaceuticals Ltd, South 20mg + Adrenaline Injection Africa Locaine A Injection Tartrate 12ug/ml 52 Efavirenz 600mg POM Tablet Film Coated 111/030 Adcock Ingram Pharmaceuticals Ltd, South Adco - Efavirenz 600 Tablets 53 Africa Efavirenz 200mg POM capsule Oral 111/031 Adcock Ingram Pharmaceuticals Ltd, South Adco Efavirenz 200 Capsules 54 Africa Medi - keel A Blackcurrant Benzocaine 12.0mg + P Lozenges 111/032 Adcock Ingram Pharmaceuticals Ltd, South 55 Throat Lozenges Cetylpyridinium 1.5mg Africa Medi - Keel A Honey and Lemon Benzocaine 12.0mg + P Lozenges 111/033 Adcock Ingram Pharmaceuticals Ltd, South 56 Throat Lozenges Cetylpyridinium 1.5mg Africa Theophylline 100mg + P Syrup 111/034 Adcock Ingram Pharmaceuticals Ltd, South Etofyline 10mg + Africa Actophlem Cough Syrup Diphenylpyramine 8mg + 57 Ammonium 720mg Page 4 of 320 ZAMBIA MEDICINES REGULATORY AUTHORITY MEDICINES FOR HUMAN USE 2019 REGISTER Prednisolone 15mg/5ml POM Syrup 111/035 Adcock Ingram Pharmaceuticals Ltd, South Prelone Syrup 58 Africa Dextromethophan P Syrup 111/036 Adcock Ingram Pharmaceuticals Ltd, South Dilinct Dry Cough Syrup Hydrobromide Ph. Eur Africa 59 15mg/5ml Tramadol Hydrochloride POM Capsule Oral 060/001 Adlife Healthare Pvt Ltd, India Dolo Doc Capsules 60 BP 50mg Amoxycillin Trihdyrate POM Suspension for 060/002 Adlife Healthare Pvt Ltd, India Amoxycillin Oral Suspension 61 125mg/5ml Oral Use SNP IMMUNOboost Tablets Sida cordiflia (Bala) P Capsule oral 449/001L Adventura Investments Limited 150mg + Tinospora 62 cordiflia (Giloya) SNP JOINTcare Tablets Shallaki (Boswelia P Tablet Uncoated 449/002L Adventura Investments Limited serrata) 300mg + Rasna 63 (Pluchea lanceolat Snp Allergy Care Tablets Inula racemose P Tablet Uncoated 449/003L Adventura Investments Limited (Pushkarmool) 75mg
Load more

Recommended publications
  • Consumer Superbrands 2019 Top 10 Consumer Superbrands Relevancy
    Consumer Superbrands 2019 Top 10 Consumer Superbrands BRAND CATEGORY LEGO 1 Child Products - Toys and Education Apple 2 Technology - General Gillette 3 Toiletries - Men's Grooming Rolex 4 Watches British Airways 5 Travel - Airlines Coca-Cola 6 Drinks - Non-Alcoholic - Carbonated Soft Drinks Andrex 7 Household - Kitchen Rolls, Toilet Roll and Tissues Mastercard 8 Financial - General Visa 9 Financial - General Dyson 10 Household & Personal Care Appliances Relevancy Index Top 20 BRAND CATEGORY Amazon 1 Retail - Entertainment & Gifts Aldi 2 Retail - Food & Drink Macmillan Cancer Support 3 Charities Netflix 4 Media - TV Google 5 Social, Search & Comparison Sites Lidl 6 Retail - Food & Drink PayPal 7 Financial - General LEGO 8 Child Products - Toys and Education Samsung 9 Technology - General YouTube 10 Social, Search & Comparison Sites Visa 11 Financial - General Heathrow 12 Travel - Airports Purplebricks 13 Real Estate Cancer Research UK 14 Charities Oral-B 15 Toiletries - Oral Care Apple 16 Technology - General Dyson 17 Household & Personal Care Appliances TripAdvisor 18 Travel - Agents & Tour Operators Nike 19 Sportswear & Equipment Disney 20 Child Products - Toys and Education continues... Consumer Superbrands 2019 Category Winners CATEGORY BRAND Automotive - Products Michelin Automotive - Services AA Automotive - Vehicle Manufacturer Mercedes-Benz Charities Cancer Research UK Child Products - Buggies, Seats and Cots Mamas & Papas Child Products - General JOHNSON'S Child Products - Toys and Education LEGO Drinks - Alcoholic - Beer, Ale
    [Show full text]
  • Faqs on COVID-19 Vaccine
    COVID-19 Frequently Asked Questions COVID-19 Vaccines About COVID-19 Vaccines Q: Why is a COVID-19 vaccine needed if social distancing and wearing masks prevent the COVID-19 virus from spreading? A: Vaccines boost your immune system, so it will be ready to fight the virus if you are exposed. Vaccination combined with ongoing prevention efforts including wearing face masks that cover the mouth and nose, frequent hand washing and staying at least 6 feet away from others offer the best protection against COVID-19. Q: How many COVID-19 vaccines are available? Which one should I get? A: In the United States, three COVID-19 vaccines have been granted emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) and recommended for use by the Centers for Disease Control and Prevention (CDC). These vaccines, manufactured by Pfizer, Moderna, and Johnson & Johnson (Janssen), have all been proven safe and effective at preventing serious illness, hospitalization, and death from COVID-19 disease. The CDC recommends getting the first vaccine available to you for protection from COVID-19. While vaccine supply is limited, individuals likely will not get to choose which vaccine to receive, and will be given what is available from their vaccine provider at the time they receive their immunization. Q: Are all of the COVID-19 vaccines effective? A: Yes. COVID-19 vaccines from Pfizer, Moderna and Johnson & Johnson (Janssen) have been approved for emergency use by the FDA, and recommended for use by the CDC after a rigorous analysis proved their effectiveness. During studies, all the vaccines were shown to prevent serious illness from COVID-19 at high effectiveness rates.
    [Show full text]
  • Specifications of Approved Drug Compound Library
    Annexure-I : Specifications of Approved drug compound library The compounds should be structurally diverse, medicinally active, and cell permeable Compounds should have rich documentation with structure, Target, Activity and IC50 should be known Compounds which are supplied should have been validated by NMR and HPLC to ensure high purity Each compound should be supplied as 10mM solution in DMSO and at least 100µl of each compound should be supplied. Compounds should be supplied in screw capped vial arranged as 96 well plate format.
    [Show full text]
  • 2015 Annual Report
    ANNUAL REPORT 2015 MARCH 2016 TO OUR SHAREHOLDERS ALEX GORSKY Chairman, Board of Directors and Chief Executive Officer This year at Johnson & Johnson, we are proud this aligned with our values. Our Board of WRITTEN OVER to celebrate 130 years of helping people Directors engages in a formal review of 70 YEARS AGO, everywhere live longer, healthier and happier our strategic plans, and provides regular OUR CREDO lives. As I reflect on our heritage and consider guidance to ensure our strategy will continue UNITES & our future, I am optimistic and confident in the creating better outcomes for the patients INSPIRES THE long-term potential for our business. and customers we serve, while also creating EMPLOYEES long-term value for our shareholders. OF JOHNSON We manage our business using a strategic & JOHNSON. framework that begins with Our Credo. Written OUR STRATEGIES ARE BASED ON over 70 years ago, it unites and inspires the OUR BROAD AND DEEP KNOWLEDGE employees of Johnson & Johnson. It reminds OF THE HEALTH CARE LANDSCAPE us that our first responsibility is to the patients, IN WHICH WE OPERATE. customers and health care professionals who For 130 years, our company has been use our products, and it compels us to deliver driving breakthrough innovation in health on our responsibilities to our employees, care – from revolutionizing wound care in communities and shareholders. the 1880s to developing cures, vaccines and treatments for some of today’s most Our strategic framework positions us well pressing diseases in the world. We are acutely to continue our leadership in the markets in aware of the need to evaluate our business which we compete through a set of strategic against the changing health care environment principles: we are broadly based in human and to challenge ourselves based on the health care, our focus is on managing for the results we deliver.
    [Show full text]
  • Northern Ireland Prescription Code Book Drugs Section September 2021
    Family Practitioner Services, Pharmaceutical Services, 2 Franklin Street, Belfast BT2 8DQ Telephone No. 028 9053 5613, Fax No. 028 9053 2963 Northern Ireland Prescription Code Book Drugs section September 2021 Page 1 of 587 Effective for prescriptions dispensed September 2021 BSO Code dm+d Pack Description Code Number Special ZD Of Container 38960 4SURE beta-ketone testing strips 4S-810-4183401-001 (Nipro Diagnostics (UK) Ltd) 10 strip strips 38961 4SURE testing strips (Nipro Diagnostics (UK) Ltd) 50 strip strips 4144 AAA 1.5mg/dose sore throat spray (Manx Healthcare Ltd) 60 dose [BSO pack = 1] BSO Unit Of Measure Code No. devices dispensed 70598 (DT) Abacavir 600mg / Lamivudine 300mg tablets 30 tablet tablets 9154 Abasaglar 100units/ml solution for injection 3ml cartridges (Eli Lilly and Company Ltd) 5 cartridge cartridges ZD 9038 Abasaglar KwikPen 100units/ml solution for injection 3ml pre-filled pens (Eli Lilly and Company Ltd) 5 pre- injections ZD filled disposable injection 70088 (DT) Abatacept 125mg/1ml solution for injection pre-filled disposable devices 4 pre-filled disposable injections ZD injection 70089 (DT) Abatacept 125mg/1ml solution for injection pre-filled syringes 4 pre-filled disposable injection injections ZD 70144 Abelcet 100mg/20ml concentrate for suspension for infusion vials (Teva UK Ltd) 10 vial vials Hospital Only 3303 Abidec Multivitamin drops (Omega Pharma Ltd) 25 ml mls 4043 Abilify 10mg orodispersible tablets (Otsuka Pharmaceuticals (U.K.) Ltd) 28 tablet 4 x 7 tablets tablets 3006 Abilify 10mg tablets (Otsuka
    [Show full text]
  • No. 33981 2 No
    Pretoria, 4 February 2011 Februarle No. 33981 2 No. 33981 GOVERNMENT GAZETTE, 4 FEBRUARY 2011 IMPORTANT NOTICE The Government Printing Works will not be held responsible for faxed documents not received due to errors on the fax machine or faxes received which are unclear or incomplete. Please be advised that an "OK" slip, received from a fax machine, will not be accepted as proof that documents were received by the GPW for printing. If documents are faxed to the GPW it will be the sender's respon­ sibility to phone and confirm that the documents were received in good order. Furthermore the Government Printing Works will also not be held responsible for cancellations and amendments which have not been done on original documents received from clients. CONTENTS INHOUD Bladsy Koerant Page Gazette No. No. No. No. No. No. GENERAL NOTICE ALGEMENEKENNISGEWING Health, Department of Gesondheld, Departement van General Notice A/gemene Kennisgewing 58 Medicines and Related Substances Act 58 Wet op Beheer van Medisyne en (101/1965): Medicines Control Council: Verwante Stowwe (101/1965): Conditions of registration of a medicine Medisynebeheerraad: Voorwaardes vir in terms of the provisions of section die registrasie van 'n medisyne in terme 15 (7) ..................................................... .. 3 33981 van die bepalings van artikel 15 (7) ........ 4 33981 STAATSKOERANT, 4 FEBRUARIE 2011 No. 33981 3 GENERAL NOTICE ALGEMENE KENNISGEWING NOTICE 58 OF 2011 MEDICINES CONTROL COUNCIL CONDITIONS OF REGISTRATION OF A MEDICINE IN TERMS OF THE PROVISIONS OF SECTION 15(7) OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965) 1. The applicant shall ensure that the medicine is manufactured and controlled in terms of the current Good Manufacturing Practices as determined by Council 2.
    [Show full text]
  • Betterbusiness Betterfinancials How We Drive Growth and Outperformance
    Reckitt Benckiser Group plc Annual Report and Financial2015 Statements betterbusiness 2015 Reckitt Benckiser Group plc (RB) Annual Report and Financial Statements We make a difference to people’s lives through a trusted portfolio of brands, across consumer health, hygiene and home. Our vision Our purpose A world where people are To make a difference, by healthier and live better. giving people innovative solutions for healthier lives and happier homes. Our strategy betterbusiness betterfinancials How we drive growth and outperformance Chief Executive’s Review on pages 8–9 bettersociety betterenvironment How we support How we reduce our communities and our environmental develop our people impact Strategic framework on pages 12–13 Contents Strategic Report bettersociety Governance Report 1 Highlights 24 – Workplace 46 Board of Directors 2 At a glance 26 – Communities 50 Executive Committee 4 Chairman’s Statement 26 – Products 52 Chairman’s Statement on 7 Reasons why RB delivers betterenvironment Corporate Governance 8 Chief Executive’s Review 27 – Greenhouse gas emissions 54 Corporate Governance Statement 10 Our unique culture 28 – Water 60 Nomination Committee Report 12 Strategic framework 28 – Waste 61 Audit Committee Report 14 Our market and resources 29 – Sourcing 66 Directors’ Remuneration Report betterfinancials 30 Our operating model 68 Our remuneration at a glance 16 – Our strategy to deliver 32 Our operating model in action 70 Annual Report on Remuneration 17 – Organisation 34 Creating stakeholder value 79 Directors’ Remuneration Policy 19 – Powermarkets 36 Financial Review 85 Report of the Directors 20 – Powerbrands 40 Strategic Risks 88 Directors’ Statement of Responsibilities 22 – Virtuous earnings model Financial Statements 89 Financial Statements Any information contained in the 2015 Annual Report and Financial Statements on the price at which shares or other securities in Reckitt Benckiser Group plc have been bought or sold in the past, or on the yield on such shares or other securities, should not be relied upon as a guide to future performance.
    [Show full text]
  • Mcneil Consumer : Mdl No
    IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA IN RE: MCNEIL CONSUMER : MDL NO. 2190 HEALTHCARE, ET AL., MARKETING : AND SALES PRACTICES LITIGATION : : Applies to: : ALL ACTIONS : MEMORANDUM McLaughlin, J. July 13, 2012 This multidistrict litigation arises out of quality control problems at the defendants’ facility manufacturing over- the-counter healthcare products in Fort Washington, Pennsylvania, which led to a series of recalls of those products. The named plaintiffs assert claims for economic loss on behalf of a putative nationwide class against Johnson & Johnson (“J&J”), McNeil Consumer Healthcare (“McNeil”), and four of their executives. The plaintiffs allege that they overpaid for the defendants’ products as a result of the recalls and the defendants’ scheme to conceal or downplay the scope of the quality control problems. The defendants, who have offered a coupon or cash refund to consumers who purchased recalled drugs, have moved to dismiss the operative complaint, and assert that the named plaintiffs lack constitutional standing and have not met the applicable pleading standard. The Court will grant the defendants’ motion because the plaintiffs have not pled facts that show a cognizable injury in fact, which is required to confer Article III standing. I. Procedural Background This litigation resulted from the consolidation of ten individual actions filed around the country. Haviland v. McNeil Consumer Healthcare, No. 10-2195, was filed in this Court on May 12, 2010, asserting economic injuries arising out of the April 30, 2010 recall of over-the-counter children’s drugs by McNeil, a part of the J&J “Family of Companies.” Eight additional cases, also arising out of the April 2010 recall, were filed in district courts around the country.1 All cases asserted claims for economic injury only, with the exception of Rivera v.
    [Show full text]
  • (Esi Scheme) Laxminagar, Ajmer Road, Jaipur-302006
    DIRECTORATE, MEDICAL & HEALTH SERVICES, (E.S.I. SCHEME) LAXMINAGAR, AJMER ROAD, JAIPUR-302006 Tel/Fax 0141-2223572,www.health.rajasthan.gov.in/esi E-Mail [email protected],[email protected] Ref. No. F434/ESI/Store/LabEmp/2017/5540 Dated:01/11/2017 E- Tender Document For “E- Tender forAnalysis of Drugs, Cotton, Gauzes, Bandage & Other items” For The Office of the Director cum Ex-officio Dy. Secretary, Medical & Health Services ESI Scheme Rajasthan, Laxmi Nagar, Ajmer Road, Jaipur & attached ESIS Institutions in Rajasthan ( for the period of two years from the date of award. ) ( Non-transferable ) Price of Tender Document Rs. 2000/- Last date & time of submission of Technical & Financial Bids is 11.12.17 at 1:30 pm Date & time of online opening of Technical Bid is 11.12.17 at 3:00 pm Visit Us At http://sppp.raj.nic.in, www.dipronline.org, http://eproc.rajasthan.gov.in, www.health.rajasthan.gov.in/esi Our Address: DIRECTORATE, MEDICAL & HEALTH SERVICES, (E.S.I. SCHEME) LAXMINAGAR, AJMER ROAD, JAIPUR-302006 1/71 DIRECTORATE, MEDICAL & HEALTH SERVICES, (E.S.I. SCHEME) LAXMINAGAR, AJMER ROAD, JAIPUR-302006 Tel/Fax 0141-2223572,www.health.rajasthan.gov.in/esi E-Mail [email protected],[email protected] Ref.No.F434/ESI/Store/LabEmp/2017/ 5540 Dated:01/11/2017 E-bids in two separate bids (Technical & Financial) for the Empanelment of Analytic Testing Laboratories For The Test and Analysis of drugs, cotton, bandage, gauze & other items. Brief Details of E-Tender Estimated Cost : Rs 50 lacs EMD (Bid Security)Rs 100000/- RISL processing fees Rs 1000/- Cost of the Tender Document Rs 2000/- Performance Security 5% of contract value Services Required:- The service of analysis of drugs, cotton, gauze, bandages & other items are required in the office of the Director cum Ex- officio Dy.
    [Show full text]
  • Research & Development of Vaccines to Prevent SARS-Cov2 Infection
    Monthly update Research & development of vaccines to prevent SARS-coV2 infection Updated May 2021 Disclaimer No vaccine against COVID-19 is approved. This document does not provide guidance on what vaccine or medicines to take. Please avoid self-prescription and always refer to your doctor before making any treatment decision. This document provides a selection of updates on the research and development of vaccines for the current coronavirus infection. Those highlights are for the information of patient organisations/ groups, advocates and people living with a rare disease. EURORDIS takes reasonable steps to verify the accuracy of the information presented. This document does not constitute, and shall not be deemed or construed as, any approval or endorsement by EURORDIS of such product or entity. Updated May 2021 Contents (click to navigate in document) A ‘must-read’ introduction .................................................................................................................................................................................................................................. 4 Resources ........................................................................................................................................................................................................................................................... 5 Vaccines in development ...................................................................................................................................................................................................................................
    [Show full text]
  • Remdesivir: First Approval
    Drugs https://doi.org/10.1007/s40265-020-01378-w ADISINSIGHT REPORT Remdesivir: First Approval Yvette N. Lamb1 © Springer Nature Switzerland AG 2020 Abstract The antiviral agent remdesivir (Veklury ®; Gilead Sciences), nucleotide analogue prodrug, has broad-spectrum activity against viruses from several families. Having demonstrated potent antiviral activity against coronaviruses in preclini- cal studies, remdesivir emerged as a candidate drug for the treatment of the novel coronavirus disease 2019 (COVID- 19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, during the current global pandemic. Phase III evaluation of remdesivir in the treatment of COVID-19 commenced in early 2020 and has thus far yielded promising results. In late May 2020, Taiwan conditionally approved the use of remdesivir in patients with severe COVID-19. This was followed by a rapid succession of conditional approvals in various countries/regions including the EU and Canada. Preceding these conditional approvals, an emergency use authorization for remdesivir had been granted in the USA (on 1 May 2020) and a special approval for emergency use was granted in Japan (on 7 May 2020). This article summarizes the milestones in the development of remdesivir leading to its first conditional approval for the treatment of COVID-19. Remdesivir (Veklury®): Key points 1 Introduction A nucleotide analogue prodrug is being developed by Remdesivir (Veklury®; Gilead Sciences), a prodrug of Gilead Sciences for the treatment of COVID-19 an adenosine nucleotide analogue, is an antiviral agent with broad-spectrum activity against viruses from several Received its frst emergency use authorization on 1 May families [1–4].
    [Show full text]
  • Notice Under S66 of the Commerce Act 1986 Application by Johnson & Johnson to Acquire the Stock, Assets and Business Of
    PUBLIC COPY Notice under s66 of the Commerce Act 1986 Application by Johnson & Johnson to acquire the stock, assets and business of the Consumer Healthcare division of Pfizer Inc. COMMERCE ACT 1986: BUSINESS ACQUISITION SECTION 66: NOTICE SEEKING CLEARANCE 28 September 2006 The Registrar Business Acquisitions and Authorisations Commerce Commission PO Box 2351 Wellington Pursuant to s66(1) of the Commerce Act 1986 notice is hereby given seeking clearance of a proposed business acquisition. 518689_1.DOC 2 CONTENTS EXECUTIVE SUMMARY PART 1: TRANSACTION DETAILS 1 The business acquisition for which clearance is sought 2 The person giving this notice 3 Confidentiality 4 Participants 5 Interconnected and associated persons 6 Beneficial interests 7 Links between participants 8 Common directorships 9 Business activities of the participants 10 Reasons for the proposed acquisition PART II: IDENTIFICATION OF MARKETS AFFECTED 11 Horizontal aggregation 12 Differentiated product markets 13 Differentiated product markets 14 Vertical integration 15 Other business acquisitions PARTS III, IV AND V: CONSTRAINTS ON MARKET POWERS BY EXISTING AND POTENTIAL COMPETITION AND OTHER POTENTIAL CONSTRAINTS 16 Allergy medication 17 Products for the treatment of worms 18 Thrush treatment CERTIFICATE APPENDICES 1. Heartburn and indigestion remedies (MYLANTA and MOTILIUM) 2. Worm treatments (COMBANTRIN, VERMOX) 3. Cold, flu, nasal decongestant, cough relief and sort throat medications (CODRAL, SINUTAB, SUDAFED, BENADRYL, BRONDECON) 4. Allergy relief products (ACTIFED, SINUTAB, SUDAFED, VISINE, LIVOSTIN) 518689_1.DOC 3 5. Thrush treatments (DIFLUCAN ONE, DAKTARIN, DAKTAGOLD, NIZORAL, SPORANOX) 6. Shampoo (PREGAINE, ROGAINE, NEUTROGENA, JOHNSON’S BABY SHAMPOO) 7. Hand hygiene (PURELL and MICRO SHIELD) 8. Competitor worm treatment products 9. Multinational pharmaceutical businesses: GlaxoSmithKline, Douglas Pharmaceuticals, Alphapharm, Bayer Group 10.
    [Show full text]